A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

  • Breast Cancer
Trial Status:

Active, not recruiting

This trial runs in
Cities
  • Barranquilla
  • Bogotá
  • Buenos Aires
  • Cali
  • Ceará
  • Cercado de Lima
  • Ciudad de Guatemala
  • Ciudad de México
  • Córdoba
  • Floridablanca
  • HPR
  • KZE
  • La Habana
  • Las Condes
  • Montevideo
  • Paraná
  • Rio de Janeiro
  • Rio Grande do Sul
  • Rosario
  • San Isidro
  • San Pedro Garza García
  • Santa Catarina
  • Santiago
  • Surquillo
  • São Paulo
  • Temuco
  • Toluca de Lerdo
Trial Identifier:

NCT04158258 MO39485

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.

      Hoffmann-La Roche Sponsor
      NCT04158258 , MO39485 Trial Identifier
      Bevacizumab, Trastuzumab, Ado-trastuzumab emtamsine, Pertuzumab, Atezolizumab, Capecitabine Treatments
      Breast Cancer Condition
      Official Title

      A STUDY TO OBSERVE PATIENTS CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED BREAST CANCER IN LATIN AMERICA

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      Inclusion Criteria
      • Histological confirmed newly diagnosed stage I to IV (recurrent or de novo) breast cancer no more than 12 months prior to site activation, although they can have received anti-cancer treatment during that time
      Exclusion Criteria
      • Patients not receiving treatment for breast cancer with national approved drugs according to standard of care and in line with the current summary of product characteristics (SPC) /local labeling
      • Patients not receiving the Roche studied medicinal product, but a biosimilar

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now